Bone Biologics Co. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Co. (NASDAQ:BBLG) saw a large growth in short interest in January. As of January 31st, there was short interest totalling 155,000 shares, a growth of 105.0% from the January 15th total of 75,600 shares. Based on an average daily trading volume, of 185,000 shares, the days-to-cover ratio is currently 0.8 days. Currently, 29.1% of the shares of the stock are short sold.

Bone Biologics Stock Performance

BBLG stock opened at $1.04 on Friday. Bone Biologics has a 52 week low of $0.80 and a 52 week high of $4.49. The firm’s 50-day moving average is $1.05 and its two-hundred day moving average is $1.40.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.